What latest ASH18 data jumps to our attention?
San Diego – It’s time to put another dozen studies in the spotlight and review what we can learn from the existing data with a view on where we’re headed in the future.
Today’s list covers a whole gamut of targeted therapies, bispecific antibodies, CAR-T cell therapies and other immunotherapies, what’s more we have a range of targets in the list too, and not the obvious ones either.
To learn more from our latest analyses and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
On their blog earlier this month, the Broad Institute posted a nice piece wittily entitled, “Opinionome: What will be the next big –ome?”
It included a chart exploring the main -omes and -omics, as well as suggestions from experts on what they saw as the next hot thing in this space.
An interesting thing that stood out to me in this timely piece was the complete and utter absence of the glycome and glycomics, which would be my answer to their provocative question – maybe not necessarily as the most hyped one – but certainly as a very impactful one.
While in Copenhagen for ESMO, we took some time out to meet with a leading global expert in the obscure field of glycomics and had the pleasure of hearing what he had to say about this exciting field of research.
The research may impact not only our knowledge about how cancer progresses, but also how it can be used to design and devise better therapeutics, including CAR T cell therapies. The answers we heard may therefore surprise.
To gain more insights, Subscribers can log in…
The race to the be first to market in the United States with a CD19 directed CAR-T cell therapy is a bit like the America’s Cup Challenge Race Series – one boat/company is ahead and then another is ahead, it’s an ever changing and fluid situation…
In this post, we’re looking at questions from subscribers – so what’s in the July BSB mailbag?
* CAR T Cell Therapy: Is the recent FDA hold – that came and went in record time, a setback to Juno? Who will win the CAR-T race to market in the United States? What is the market opportunity in Europe?
* Jounce/Celgene Deal: Celgene have a reputation for doing deals with innovative biotech companies, but then what? Is the Jounce deal a good one, or is it a value destroyer?
There are a few other questions in the mail bag, but the above gives you a flavour of some of the commentary in this post.
Subscribers can login to read more or you can purchase access.